C
CLLS
Cellectis
0.9865
+0.0065+0.66%Opening12:22 10/26 EDT
OPEN/PREV CLOSE0.9800/0.9800
TODAY RANGE0.9309-1.010
VOL45.34K
MARKET CAP70.26M
52 WEEK RANGE0.8808-5.45
AVG VOL (3M)99.55K
% TURNOVER0.06%
TURNOVER--
P/E (TTM)-1.4869
% RANGE7.05%
EPS(TTM)-0.6500
P/E(FORWARD)-1.2461
P/B1.711
BVPS0.5649
DIVIDEND--
P/S0.8784
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP70.26M
SHARES OUTSTANDING72.70M
NEXT EARNINGS11/05-11/09
FREE FLOAT72.70M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·2h ago
Cellectis sees FY27 adjusted EPS $21.50
TipRanks·2h ago
Cellectis sees FY27 capital expenditures $1.5B-$2B
TipRanks·2h ago
Cellectis sees Q4 adjusted EPS $3.37-$3.57
Seeking Alpha·09/16 14:11
Cellectis: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring
Benzinga·09/16 14:10
This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
TipRanks·09/16 13:45
Starbucks initiated, Expedia downgraded: Wall Street’s top analyst calls
Benzinga·09/16 13:10
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Dow Jones·09/16 12:59
Cellectis Cut to Underweight From Overweight by Barclays
Dow Jones·09/16 12:59
Cellectis Price Target Cut to $1.30/Share From $9.00 by Barclays
Benzinga·09/16 12:50
Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3
Benzinga·09/16 12:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
TipRanks·09/16 09:00
Cellectis downgraded to Underweight from Overweight at Barclays
Seeking Alpha·09/15 17:33
Cellectis falls as Citizens downgrades on pivot to genetic medicines
Benzinga·09/15 14:04
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Same Industry
Name/Symbol
Change%
Price